Neo-volumab news.

Building off an earlier pilot trial, the phase 3 CheckMate-816 has announced it confirms the addition of nivolumab to neoadjuvant chemo for resectable non-small cell lung cancer improves pathologic complete response rates. | Bristol Myers Squibb 2020

Comments

Popular Posts